Profit

Buy Granules India For Target Of Rs 156: Mahantesh Sabarad

PUBLISHED ON: August 17, 2016 | Duration: 21 min, 34 sec

  
loading..
Mahantesh Sabarad, deputy vice president (research) at SBICap Securities, says Granules India, which was earlier into manufacturing of active pharmaceutical ingredients, is now getting into abbreviated new drug application filings. He expects a topline growth of more than 20 per cent for the company.
ALSO WATCH
GST Impact On Stock Markets

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com